HPTN
Jul 7, 2020 | News
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...
May 19, 2020 | In the Media, News
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC)...
Jul 22, 2019 | In the Media, News
HPTN 071 (PopART) examined the impact of a package of HIV prevention interventions, including universal testing and treatment, on community-level HIV incidence amongst more than one million people living in 21 urban and peri-urban communities in Zambia and South...
Jul 11, 2019 | News
ICAP at Columbia University is playing a key role in testing the feasibility of a potential breakthrough in the global effort to stop HIV transmission. The Harlem Prevention Center, one of ICAP’s two clinical research centers in New York, is participating in a...
Mar 5, 2019 | In the Media, News
The HPTN 071 (PopART) study involved more than a million people living in 21 communities in Zambia and South Africa‚ making it the largest HIV-prevention trial to date. The study measured the effects of two HIV-combination prevention strategies offering HIV testing to...